Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma

NCT01171482 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped There were problems with national reimbursement policies.

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: 5-FU
DRUG: Mitomycin
DRUG: sorafenib

Sponsor

Seoul National University Hospital